Virtual KOL Discussion of Updated Study 1100 Data at ASCO 2021

Program:
8 am EDT (2 pm CEST) : Opening Remarks
Jeffrey Bockman, PhD, EVP, Oncology Practice Head, Cello Health BioConsulting

8:05 am : NBTXR3 Mode of Action
Laurent Levy, PhD, CEO and Founder, Nanobiotix

8:10 am : Overview of Treatment Landscape : Promise and Limitations of Immunotherapy, and Rationale for Combination-based Approaches
Jared Weiss, MD, Assistant Professor of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center

8:20 am : Nanobiotix Study 1100 Safety and Efficacy Data Update
Tanguy Seiwert, MD, Assistant Professor of Oncology, Director, Head and Neck Cancer Oncology Disease Group, Johns Hopkins Medicine, and Colette Shen, MD, PhD, Assistant Professor, Radiation Oncology, University of North Carolina Lineberger Comprehensive Cancer Center

8:40 am : NBTXR3 as a Potential Combo agnostic Product, Rationale and Future Opportunity
James Welsh, MD, Associate Professor, University of Texas, MD Anderson Cancer Center

8:50 am : Discussion and Q&A- Implications of Study 1100 in Head and Neck and beyond

9:10 am : Summary Close
Jeffrey Bockman, PhD, EVP, Oncology Practice Head, Cello Health BioConsulting